Microbot Medical Inc. (MBOT)
Company Description
Microbot Medical Inc. operates as a pre-clinical medical device company in the United Kingdom.
It primarily engages in the research, design, and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space.
The company also offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.
In addition, it provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter.
The company also has a strategic collaboration agreement with Stryker Corporation for technology co-development.
Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.
Country | United States |
Founded | 2010 |
Industry | Medical Instruments & Supplies |
Sector | Healthcare |
Employees | 18 |
CEO | Harel Gadot |
Contact Details
Address: 25 Recreation Park Dr Suite 108 Hingham, Massachusetts 02043 United States | |
Phone | 908-938-5561 |
Website | microbotmedical.com |
Stock Details
Ticker Symbol | MBOT |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000883975 |
CUSIP Number | 59503A204 |
ISIN Number | US59503A2042 |
Employer ID | 94-3078125 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Harel Gadot | Co-Founder, President, Chief Executive Officer and Chairman |
Yoseph Bornstein | Co-Founder and Independent Director |
Rachel Vaknin | Chief Financial Officer |
Dr. Simon Sharon MBA, MSc | Chief Technology Officer and GM of Microbot Israel |
Dr. Juan Diaz-Cartelle | Chief Medical Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 27, 2024 | 10-K | Annual Report |
Feb 27, 2024 | 8-K | Current Report |
Feb 20, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jan 30, 2024 | 424B3 | Prospectus |
Jan 30, 2024 | 8-K | Current Report |
Jan 25, 2024 | EFFECT | Notice of Effectiveness |
Jan 22, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
Jan 19, 2024 | UPLOAD | Filing |
Jan 18, 2024 | 8-K | Current Report |